PDCD1LG2 and neoplasm: From a clinical perspective, the most crucial peripheral checkpoint inhibitor pathway exploited by tumour cells within the TME identified to date is the interaction between the PD-1 receptor on T cells with its programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) on tumour cells.